Cell Based Assays for Botulinum Neurotoxins Serotype-Specific

USPTO published patent application US20260092255A1 covering cell-based assays for botulinum neurotoxin characterization and the genetically modified cells utilized in such assays. The application discloses methods allowing discrimination between different serotypes of clostridium neurotoxins having the same SNARE protein substrate specificity—a capability absent in parental cell lines—without relying on serotype-specific neutralizing antibodies or competing heavy chains derived from Clostridia botulinum neurotoxin.

This is a published patent application (A1 publication) under the patent classification C12N (Biotechnology). No compliance actions, deadlines, or regulatory requirements are imposed on any party. The publication represents an intellectual property filing under USPTO procedures. No penalties or enforcement actions are associated with this document. Entities with relevant research interests may review the claims to assess potential patent landscape considerations.